PYRAZINAMIDE


Trade Names	PYRAZINAMIDE
Synonyms	.alpha.-pyrazinamide Aldinamid Aldinamide D-50 Eprazin Farmizina Isopas MK-56 NSC-14911 Novamid Pirazimida Pirazinamid Pirilene Pyrafat Pyramizade Pyrazide Pyrazinamide Pyrazinamidum Pyrazine carboxylamide Pyrazinecarboxamide Rozide Tebrazid Unipyranamide Zinamide
Status
Molecule Category	Free-form
ATC	J04AK01
UNII	2KNI5N06TI
EPA CompTox	DTXSID9021215


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	IPEHBUMCGVEMRF-UHFFFAOYSA-N
Smiles	NC(=O)c1cnccn1
InChI	InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)

Pharmacology

Mechanism of Action	Action	Reference
70S ribosome inhibitor	INHIBITOR	PubMed Wikipedia

Cross References

Resources	Reference
ChEBI	45285
ChEMBL	CHEMBL614
DrugBank	DB00339
DrugCentral	2328
FDA SRS	2KNI5N06TI
Human Metabolome Database	HMDB0014483
Guide to Pharmacology	7287
KEGG	C01956
PDB	PZA
PharmGKB	PA451182
PubChem	1046
SureChEMBL	SCHEMBL24102
ZINC	ZINC000000002005

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).